Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AML
Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Danielle Hammond, MD, a clinical fellow in leukemia for the MD Anderson Cancer Center Leukemia Fellowship Program at The University of Texas MD Anderson Cancer Center, discusses the results from a retrospective review of patients with acute myeloid leukemia (AML) treated over the last 6 years with a combination of venetoclax (Venclexta) and either decitabine or azacitadine.
This combination was highly effective in patients with IDH-mutated AML in the front line with a complete response (CR) and CR with incomplete hematologic recovery (CRi) rate of about 88%, according to Hammond. The patients with relapsed/refractory disease had a CR and CRi rate of close to 50%.
Using flow cytometry for minimal residual disease (MRD) testing in the patients receiving frontline treatment, investigators found that almost 90% of the patients who responded to treatment had MRD negativity. Hammond says what is interesting is that half of the responding patients, despite being MRD negative by flow cytometry, still had a detectable IDH mutation when using next generation sequencing. This suggests there may be a role for combination therapy with the FDA approved IDH1 and IDH2 inhibitors, she concluded.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
